FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2550498581> ?p ?o ?g. }

• W2550498581 abstract "Abstract Abstract 3622 Background: AML is a group of heterogeneous malignant diseases characterized by uncontrolled cell growth and differentiation arrest. Following the success of differentiating therapies in APL, great hopes were placed in Vitamin D (VD) and its ability to promote differentiation of non-APL AML cells. However, results of clinical studies were disappointing and trials were interrupted due to the occurrence of life-threatening hypercalcemia. Our group has shown that iron chelators such as deferasirox (DFX) are able to promote monocytes differentiation in both normal hematopoietic progenitors and AML cells (Callens et al Jexp Med 2010). Moreover, iron deprivation synergized with VD to promote cell differentiation on leukemic cells. Most elderly patients diagnosed with AML suffer from secondary iron overload because of in some cases ineffective erythropoiesis and iterative red blood cell transfusions. Furthermore, in myelodysplastic syndromes, retrospective studies have suggested that iron chelators may increase life expectancy and decrease the risk of transformation into AML. In AML of the elderly, the use of demethylating agents such as 5-azacytidine or decitabine may induce hematological response and increase life expectancy. However, response is often of short duration. Since VD deficiency and iron overload prevalence is high in the elderly, the association of VD and DFX was given to a subgroup of patients following demethylating agents failure. Methods: A retrospective chart review of 17 elderly AML patients after demethylating agents failure was performed in three French centers. Patients treated by the combination of DFX/VD were matched to patients treated with best supportive care (BSC). Based on ferritin, and creatinin levels the dose of DFX was adapted in each case. DFX dose was up to 2000 mg a day and VD was used at 100,000 units orally weekly. The tolerance and the overall survival (OS) were analyzed. Pre-clinical studies were conducted in vitro on cell lines (HL60, U937, OCI-AML3, THP-1, MOLM 13) to evaluate cell differentiation induced by DFX and a new VDR agonist (Inecalcitol) by cell morphology and flow cytometry (expression of CD11b and CD14 markers). VDR activity and expression were evaluated by flow cytometry, immunoblotting, luciferase reporter assays and qPCR to detect VDR-targeted genes. Results: Median age of DFX/VD patients and BSC control group were 76 (range 63–84) and 71 (58–85) respectively. Most patients were diagnosed with AML with multilineage dysplasia (cases 70%, controls 76%). Prognosis groups were distributed homogeneously between the treated patients and controls. There were no significant differences in blast infiltration, leukocytosis, neutropenia, systemic iron and phosphocalcium parameters. All patients received 5-azacytidine (median of 8 courses for the cases and 7 for the controls).No renal insufficiency, hepatotoxicity or hypercalcemia were observed in DFX/VD patients. At 3 months, 4 treated patients (23.5%) had significant monocyte level increase an evidence of the enhanced monocyte differentiation efficacy. The treatment did not decrease the need of transfusion. Most interestingly median survival of treated patients was significantly increased (10.4 m vs 4 m, p=0.002). In vitro studies were conducted in parallel aiming to characterize new potential alternative therapeutic associations, which could improve patients' response. We show that the use of a new highly potent VDR agonist (Inecalcitol) potentiated the effect of DFX in promoting terminal monocyte differentiation of leukemic cell lines. It also increased VDR activity evaluated by VDR expression and phosphorylation and expression of VDR-targeted genes. In vivo studies in mice model of AML using combined DFX/inecalcitol therapy will be presented. Conclusions: The prognosis of elderly patients diagnosed with AML after demethylating agents remains poor. Here we show that the differentiating therapy by the association of Deferasirox and Vitamin D was able to improve overall survival with low toxicity. New generation of highly-potent VDR agonists (which are devoided of hypercalcemic properties) significantly enhanced VDR activation and terminal monocyte differentiation of AML cells and represent potential therapeutic alternatives in the near future. These encouraging results should be verified in a large randomized prospective multicenter study. Disclosures: No relevant conflicts of interest to declare." @default.
• W2550498581 created "2016-11-30" @default.
• W2550498581 creator A5026922298 @default.
• W2550498581 creator A5027696743 @default.
• W2550498581 creator A5031765620 @default.
• W2550498581 creator A5033775906 @default.
• W2550498581 creator A5036122955 @default.
• W2550498581 creator A5058365219 @default.
• W2550498581 creator A5062422990 @default.
• W2550498581 creator A5064856085 @default.
• W2550498581 creator A5067916177 @default.
• W2550498581 creator A5071098590 @default.
• W2550498581 creator A5072928493 @default.
• W2550498581 creator A5083238922 @default.
• W2550498581 creator A5086300417 @default.
• W2550498581 date "2012-11-16" @default.
• W2550498581 modified "2023-10-18" @default.
• W2550498581 title "Association of Deferasirox and Vitamin D Promotes Cell Differentiation and Improves Overall Survival in Acute Myeloid Leukemia (AML) Elderly Patients After Demethylating Agents Failure: A Retrospective Case Control Study" @default.
• W2550498581 doi "https://doi.org/10.1182/blood.v120.21.3622.3622" @default.
• W2550498581 hasPublicationYear "2012" @default.
• W2550498581 type Work @default.
• W2550498581 sameAs 2550498581 @default.
• W2550498581 citedByCount "0" @default.
• W2550498581 crossrefType "journal-article" @default.
• W2550498581 hasAuthorship W2550498581A5026922298 @default.
• W2550498581 hasAuthorship W2550498581A5027696743 @default.
• W2550498581 hasAuthorship W2550498581A5031765620 @default.
• W2550498581 hasAuthorship W2550498581A5033775906 @default.
• W2550498581 hasAuthorship W2550498581A5036122955 @default.
• W2550498581 hasAuthorship W2550498581A5058365219 @default.
• W2550498581 hasAuthorship W2550498581A5062422990 @default.
• W2550498581 hasAuthorship W2550498581A5064856085 @default.
• W2550498581 hasAuthorship W2550498581A5067916177 @default.
• W2550498581 hasAuthorship W2550498581A5071098590 @default.
• W2550498581 hasAuthorship W2550498581A5072928493 @default.
• W2550498581 hasAuthorship W2550498581A5083238922 @default.
• W2550498581 hasAuthorship W2550498581A5086300417 @default.
• W2550498581 hasConcept C104317684 @default.
• W2550498581 hasConcept C126322002 @default.
• W2550498581 hasConcept C143998085 @default.
• W2550498581 hasConcept C150194340 @default.
• W2550498581 hasConcept C190727270 @default.
• W2550498581 hasConcept C201750760 @default.
• W2550498581 hasConcept C2777799968 @default.
• W2550498581 hasConcept C2778729363 @default.
• W2550498581 hasConcept C2779282312 @default.
• W2550498581 hasConcept C2780007613 @default.
• W2550498581 hasConcept C2780235182 @default.
• W2550498581 hasConcept C2780817109 @default.
• W2550498581 hasConcept C2781053155 @default.
• W2550498581 hasConcept C28328180 @default.
• W2550498581 hasConcept C54355233 @default.
• W2550498581 hasConcept C55493867 @default.
• W2550498581 hasConcept C71924100 @default.
• W2550498581 hasConcept C86803240 @default.
• W2550498581 hasConceptScore W2550498581C104317684 @default.
• W2550498581 hasConceptScore W2550498581C126322002 @default.
• W2550498581 hasConceptScore W2550498581C143998085 @default.
• W2550498581 hasConceptScore W2550498581C150194340 @default.
• W2550498581 hasConceptScore W2550498581C190727270 @default.
• W2550498581 hasConceptScore W2550498581C201750760 @default.
• W2550498581 hasConceptScore W2550498581C2777799968 @default.
• W2550498581 hasConceptScore W2550498581C2778729363 @default.
• W2550498581 hasConceptScore W2550498581C2779282312 @default.
• W2550498581 hasConceptScore W2550498581C2780007613 @default.
• W2550498581 hasConceptScore W2550498581C2780235182 @default.
• W2550498581 hasConceptScore W2550498581C2780817109 @default.
• W2550498581 hasConceptScore W2550498581C2781053155 @default.
• W2550498581 hasConceptScore W2550498581C28328180 @default.
• W2550498581 hasConceptScore W2550498581C54355233 @default.
• W2550498581 hasConceptScore W2550498581C55493867 @default.
• W2550498581 hasConceptScore W2550498581C71924100 @default.
• W2550498581 hasConceptScore W2550498581C86803240 @default.
• W2550498581 hasLocation W25504985811 @default.
• W2550498581 hasOpenAccess W2550498581 @default.
• W2550498581 hasPrimaryLocation W25504985811 @default.
• W2550498581 hasRelatedWork W125135411 @default.
• W2550498581 hasRelatedWork W1983181789 @default.
• W2550498581 hasRelatedWork W2050400868 @default.
• W2550498581 hasRelatedWork W2073802053 @default.
• W2550498581 hasRelatedWork W2099231886 @default.
• W2550498581 hasRelatedWork W2185390754 @default.
• W2550498581 hasRelatedWork W2276292822 @default.
• W2550498581 hasRelatedWork W2392982995 @default.
• W2550498581 hasRelatedWork W2461961057 @default.
• W2550498581 hasRelatedWork W2558560139 @default.
• W2550498581 hasRelatedWork W2560390711 @default.
• W2550498581 hasRelatedWork W2563242208 @default.
• W2550498581 hasRelatedWork W2595888193 @default.
• W2550498581 hasRelatedWork W2726350654 @default.
• W2550498581 hasRelatedWork W2898815229 @default.
• W2550498581 hasRelatedWork W2921604563 @default.
• W2550498581 hasRelatedWork W2979810047 @default.
• W2550498581 hasRelatedWork W3175579773 @default.
• W2550498581 hasRelatedWork W3212725790 @default.
• W2550498581 hasRelatedWork W960845059 @default.
• W2550498581 isParatext "false" @default.
• W2550498581 isRetracted "false" @default.
• W2550498581 magId "2550498581" @default.
• W2550498581 workType "article" @default.